Search
Nelfinavir
go.drugbank.com/drugs/DB00220ApprovedInvestigationalIt is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
Paromomycin
go.drugbank.com/drugs/DB01421ApprovedInvestigationalAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalIt is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides.
Ubenimex
go.drugbank.com/drugs/DB03424InvestigationalIt is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337Approved[L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.
Ketazolam
go.drugbank.com/drugs/DB01587ApprovedWithdrawnKetazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Povidone
go.drugbank.com/drugs/DB11061ApprovedInvestigationalWithdrawnIt is also used in many technical applications with various roles as an adhesive, additive, and emulsifier. … The clinical effectiveness of [DB06812] on wound healing remains somewhat controversial, as it was demonstrated in a few clinical studies that the application of the compound in wounds was associated with
Mixtures: Premier Value Eye Drops MtProducts: VIDISEPT EDO EIN DOSISDanaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnThe use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. … It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients.
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigational[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Diazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity.